Milnacipran Micro Labs (Milnacipran Hydrochloride)

Milnacipran, the active ingredient in Milnacipran Micro Labs, is a Serotonin‑Norepinephrine Reuptake Inhibitor (SNRI) presented as an oral tablet for systemic oral administration. It is indicated for the management of major depressive disorder and for alleviating pain in fibromyalgia patients.

GNH USA supplies Milnacipran Micro Labs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with capabilities for bulk manufacturing, quality assurance, and regulatory support across EU and global markets. The company adheres to stringent GMP standards and provides reliable logistics for timely delivery.

Milnacipran, an SNRI, is used in disorders where modulation of serotonin and norepinephrine pathways improves mood and pain perception. - Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Fibromyalgia: lessens widespread musculoskeletal pain and enhances functional capacity. - Depressive symptoms associated with chronic pain: provides dual benefit of mood elevation and pain relief in patients experiencing both conditions.

Milnacipran may be associated with a range of adverse reactions, varying from mild to serious. Common Side Effects: - Nausea - Headache - Dry mouth - Insomnia Serious or Rare Side Effects: - Suicidal thoughts or behaviors - Hypertension - Serotonin syndrome

When prescribing milnacipran, clinicians should consider several safety measures. - Assess cardiovascular status: monitor blood pressure and heart rate before and during therapy. - Screen for psychiatric history: watch for emergence of suicidal ideation, especially early in treatment. - Avoid abrupt discontinuation: taper dose under medical supervision to reduce withdrawal symptoms. - Use caution in hepatic impairment: consider dose adjustment or close monitoring. - Store at ambient temperature: keep in original container, protect from moisture and light.

Milnacipran can interact with several medication classes, requiring careful management. Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis and serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants): increased serotonin syndrome risk. - Linezolid or methylene blue: potent MAO inhibition leading to severe reactions. Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase milnacipran plasma levels. - Antihypertensive drugs: additive blood pressure‑lowering effect. - NSAIDs: may increase risk of gastrointestinal bleeding.